I. Nagaraju

The development of an immediate release (IR) dosage form can minimize the problems associated with controlled release systems of etodolac tablets with its higher ability to release drug into blood circulation, increased bioavailability and patient acceptability. In the present study, an effort has made to formulate and evaluate an immediate release etodolac tablet works against the rheumatoid arthritis and human prostate cancer. These immediate release etodolac tablets were prepared by wet granulation process. Eighteen formulation trials were taken to optimize the final formula. From these, formulation F18 have been optimized as a final formulation. Pre-formulation studies were evaluated to measure the flow properties of pre-compressed powder blend of formulations. Then, post-compression studies include weight variation, thickness, hardness were conducted to evaluate the physical parameters of the final formulation. In vitro drug release studies were conducted to know the intrinsic drug releasing ability of etodolac tablets in dissolution medium. In addition, IR etodolac tablets shown a good stability profile. All results from pre and post-formulation studies were within the acceptable limits which are prescribed by USP. These results suggesting that optimized F18 was a stable formulation, suitable for preparation of immediate release etodolac tablet and also has good dissolution profile with that of innovator product.